Lord CJ - Search Results

1

Opinion: PARP inhibitors in cancer-what do we still need to know?

Wicks AJ, Krastev DB, Pettitt SJ, Tutt ANJ, Lord CJ. Wicks AJ, et al. Among authors: lord cj. Open Biol. 2022 Jul;12(7):220118. doi: 10.1098/rsob.220118. Epub 2022 Jul 27. Open Biol. 2022. PMID: 35892198 Free PMC article. Review.

2

DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.

Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A. Gudmundsdottir K, et al. Among authors: lord cj. EMBO Rep. 2004 Oct;5(10):989-93. doi: 10.1038/sj.embor.7400255. Epub 2004 Sep 10. EMBO Rep. 2004. PMID: 15359272 Free PMC article.

3

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Farmer H, et al. Among authors: lord cj. Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445. Nature. 2005. PMID: 15829967 Free article.

4

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. McCabe N, et al. Among authors: lord cj. Cancer Biol Ther. 2005 Sep;4(9):934-6. doi: 10.4161/cbt.4.9.2141. Epub 2005 Sep 1. Cancer Biol Ther. 2005. PMID: 16251802

5

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Tutt AN, et al. Among authors: lord cj. Cold Spring Harb Symp Quant Biol. 2005;70:139-48. doi: 10.1101/sqb.2005.70.012. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869747

6

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. McCabe N, et al. Among authors: lord cj. Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140. Cancer Res. 2006. PMID: 16912188

7

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A. Iorns E, et al. Among authors: lord cj. Cancer Cell. 2008 Feb;13(2):91-104. doi: 10.1016/j.ccr.2008.01.001. Cancer Cell. 2008. PMID: 18242510 Free article.

8

Resistance to therapy caused by intragenic deletion in BRCA2.

Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Edwards SL, et al. Among authors: lord cj. Nature. 2008 Feb 28;451(7182):1111-5. doi: 10.1038/nature06548. Epub 2008 Feb 10. Nature. 2008. PMID: 18264088

9

DNA repair deficiency as a therapeutic target in cancer.

Martin SA, Lord CJ, Ashworth A. Martin SA, et al. Among authors: lord cj. Curr Opin Genet Dev. 2008 Feb;18(1):80-6. doi: 10.1016/j.gde.2008.01.016. Epub 2008 Mar 14. Curr Opin Genet Dev. 2008. PMID: 18343102 Review.

10

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A. Turner NC, et al. Among authors: lord cj. EMBO J. 2008 May 7;27(9):1368-77. doi: 10.1038/emboj.2008.61. Epub 2008 Apr 3. EMBO J. 2008. PMID: 18388863 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

250 results

Search Page